Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic

Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors. Also participating in the round were new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi and existing investors Wellington Management, RA Capital Management and Moore Strategic Ventures.